Intercept Pharmaceuticals | ICPT - Frais De Vente Et D'Administration



Frais De Vente Et D'Administration Changement Date
Acadia Pharmaceuticals USD 146.73M 21.82M 2025-12
Alnylam Pharmaceuticals USD 285.06M 22.47M 2025-12
Amarin USD 18.97M 1.03M 2025-12
Amgen USD 1.94B 237M 2025-12
Arrowhead Research USD 46.02M 8.84M 2025-12
AstraZeneca USD 4.61B 4.46B 2025-12
Biogen USD 545.2M 38.6M 2025-09
Bristol-Myers Squibb USD 2.18B 392M 2025-12
Eli Lilly USD 3.13B 391.3M 2025-12
Enanta Pharmaceuticals USD -1.05 0.31 2024-12
Esperion Therapeutics USD 39.42M 456K 2025-12
Galectin Therapeutics USD 1.48M 110K 2024-06
Gilead Sciences USD 1.78B 425M 2025-12
GlaxoSmithKline GBP 2.68B 518M 2025-12
Incyte USD 390.41M 61.33M 2025-12
Ionis Pharmaceuticals USD 130M 43.43M 2025-12
Moderna USD 308M 40M 2025-12
Neurocrine Biosciences USD 301.8M 10.2M 2025-12
Novartis USD 3.44B 128M 2025-12
PTC Therapeutics USD 87.2M 3.15M 2025-12
Regeneron Pharmaceuticals USD 775M 117.2M 2025-12
Sangamo BioSciences USD 9.64M 1.83M 2024-06
Sarepta Therapeutics USD 105.38M 28.27M 2025-12
Vertex Pharmaceuticals USD 487M 41.9M 2025-12